CRISPR Therapeutics(CRSP) - 2023 Q3 - Quarterly Report

Not applicable. Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information. On September 7, 2023, Dr. Phuong Khanh Morrow, our Chief Medical Officer, adopted a trading arrangement intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) (a "Rule 10b5-1 trading arrangement") with respect to the sale of up to an aggregate of 94,699 common shares of the Company pursuant to the terms of such trading plan, inclusive of common shares that will be mandated to ...